VistaGen Therapeutics
VTGN
47 hedge funds and large institutions have $45.3M invested in VistaGen Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
9% more funds holding
Funds holding: 43 → 47 (+4)
4.05% less ownership
Funds ownership: 60.44% → 56.4% (-4%)
20% less capital invested
Capital invested by funds: $56.3M → $45.3M (-$11M)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
77% less call options, than puts
Call options by funds: $370K | Put options by funds: $1.64M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$556K |
| 2 |
Renaissance Technologies
New York
|
+$429K |
| 3 |
VU
Valence8 US
Cambridge,
Massachusetts
|
+$117K |
| 4 |
Millennium Management
New York
|
+$86.5K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$71.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.92M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.05M |
| 3 |
AC
Armistice Capital
New York
|
-$1.04M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$108K |
| 5 |
Barclays
London,
United Kingdom
|
-$67K |
VTGN Hedge Fund Activity: Q3 2024 in Review
47 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2024, worth a combined $45.3M — down 20% from $56.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VTGN positions and 3 closed out — a net gain of 4 holders — while 10 added to existing stakes and 13 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $556K. The largest seller was Great Point Partners, cutting an estimated $2.92M.
- 47 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2024, up from 43 in Q2 2024.
- Funds reported $45.3M of VistaGen Therapeutics stock for Q3 2024, down 20% quarter-over-quarter.
- 7 funds opened new VistaGen Therapeutics positions in Q3 2024 and 3 closed out, a net change of +4 holders.
- The largest VistaGen Therapeutics buyer in Q3 2024 was ADAR1 Capital Management, an estimated $556K added.
- The largest VistaGen Therapeutics seller in Q3 2024 was Great Point Partners, an estimated $2.92M sold.
Based on aggregated 13F filings for Q3 2024.